Disrupting cancer cells' biocircuits with interactome-based drugs: Is 'clinical' innovation realistic?

Expert Review of Proteomics

Volumn 9, Issue 4, 2012, Pages 349-353

  Roukos, Dimitrios H ^a,b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

drug; interactome; molecular network; protein protein interaction; signalling pathway

Indexed keywords

B RAF KINASE; BCR ABL PROTEIN; CETUXIMAB; DNA BINDING PROTEIN; FLT3 LIGAND; IMATINIB; TRASTUZUMAB; VEMURAFENIB;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER GROWTH; CANCER PATIENT; CANCER RESISTANCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL POPULATION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL PRACTICE; COLORECTAL CANCER; DNA METHYLATION; DRUG EFFICACY; DRUG INDUSTRY; DRUG RESISTANCE; DRUG SAFETY; DRUG TARGETING; EPIGENETICS; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; GENE INTERACTION; GENE MUTATION; GENE SEQUENCE; GENE STRUCTURE; GENETIC ASSOCIATION; GENETICS; GENOMICS; HUMAN; LONGEVITY; METABOLOMICS; METASTASIS; NEXT GENERATION SEQUENCING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHARMACOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PROTEIN INTERACTION; PROTEOMICS; REVIEW; RNA SEQUENCE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMS BIOLOGY; TECHNOLOGY; TREATMENT RESPONSE; TUMOR BIOPSY; WHOLE EXOME SEQUENCING; WHOLE GENOME SEQUENCING;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMEDICAL RESEARCH; DRUG DISCOVERY; DRUG RESISTANCE, NEOPLASM; GENETIC HETEROGENEITY; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84866342003     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/epr.12.37     Document Type: Review

References (25)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 144(5), 646-674 (2011).
2. Barabási AL, Gulbahce N, Loscalzo J. Network medicine: A network-based approach to human disease. Nat. Rev. Genet. 12(1), 56-68 (2011).
3. Roukos DH. Longevity with systems medicine? Epigenome, genome and environment interactions network. Epigenomics 4(2), 119-123 (2012).
4. Roy S, Ernst J, Kharchenko PV et al.; modENCODE Consortium. Identification of functional elements and regulatory circuits y Drosophila modENCODE. Science 330(6012), 1787-1797 (2010).
5. Ideker T, Krogan NJ. Differential network biology. Mol. Syst. Biol. 8, 565 (2012).
6. Roukos DH. Spatiotemporal individual genome code-lifestyle network: Revolutionizing personal diagnostics. Expert Rev. Mol. Diagn. 12(3), 215-218 (2012).
7. Alberts B. Model organisms and human health. Science 330(6012), 1724 (2010).
8. Vogelstein B, Kinzler KW. Winning the war: Science parkour. Sci. Transl. Med. 4(127), 127ed2 (2012).
9. Roberts NJ, Vogelstein JT, Parmigiani G, Kinzler KW, Vogelstein B, Velculescu VE. The predictive capacity of personal genome sequencing. Sci. Transl. Med. 4(133), 133ra58 (2012).
10. Roukos DH, Katsios C, Liakakos T. Genotype-phenotype map and molecular networks: A promising solution in overcoming colorectal cancer resistance to targeted treatment. Expert Rev. Mol. Diagn. 10(5), 541-545 (2010).
11. Katsios C, Roukos DH. Individual genomes and personalized medicine: Life diversity and complexity. Per. Med. 7(4), 347-350 (2010).
12. Roychowdhury S, Iyer MK, Robinson DR et al. Personalized oncology through integrative high-throughput sequencing: A pilot study. Sci. Transl. Med. 3(111), 111ra121 (2011).
13. Chen R, Mias GI, Li-Pook-Than J et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell 148(6), 1293-1307 (2012).
14. Stephens PJ, Tarpey PS, Davies H et al.; Oslo Breast Cancer Consortium (OSBREAC). The landscape of cancer genes and mutational processes in breast cancer. Nature 486(7403), 400-404 (2012).
15. Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366(10), 883-892 (2012).
16. Khatri P, Sirota M, Butte AJ. Ten years of pathway analysis: Current approaches and outstanding challenges. PLoS Comput. Biol. 8(2), e1002375 (2012).
17. Yeh SH, Yeh HY, Soo VW. A network flow approach to predict drug targets from microarray data, disease genes and interactome network - case study on prostate cancer. J. Clin. Bioinforma. 2(1), 1 (2012).
18. Fabbro D, Cowan-Jacob SW, Möbitz H, Martiny-Baron G. Targeting cancer with small-molecular-weight kinase inhibitors. Methods Mol. Biol. 795, 1-34 (2012).
19. Paul SM, Mytelka DS, Dunwiddie CT et al. How to improve R&D productivity: The pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 9(3), 203-214 (2010).
20. Smith CC, Wang Q, Chin CS et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 485(7397), 260-263 (2012).
21. Ross-Innes CS, Stark R, Teschendorff AE et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 481(7381), 389-393 (2012).
22. Baylin SB, Jones PA. A decade of exploring the cancer epigenome - biological and translational implications. Nat. Rev. Cancer 11(10), 726-734 (2011).
23. Dominissini D, Moshitch-Moshkovitz S, Schwartz S et al. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature 485(7397), 201-206 (2012).
24. Bodenmiller B, Wanka S, Kraft C et al. Phosphoproteomic analysis reveals interconnected system-wide responses to perturbations of kinases and phosphatases in yeast. Sci. Signal. 3(153), rs4 (2010).
25. Welch CM, Elliott H, Danuser G, Hahn KM. Imaging the coordination of multiple signalling activities in living cells. Nat. Rev. Mol. Cell Biol. 12(11), 749-756 (2011).